Dow Drops More Than 1%; Nio Stock Declines Following Q2 Earnings Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 02 2025
0mins
Should l Buy UTHR?
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones falling over 1%, while the NASDAQ and S&P 500 also experienced significant drops. Notable movements included a 2% decrease in NIO shares following disappointing quarterly results, despite a year-over-year revenue increase.
Sector and Commodity Updates: Consumer staples saw a slight increase, while information technology stocks fell. In commodities, oil and gold prices rose, and European and Asian markets mostly closed lower, reflecting a broader trend of declining equities globally.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UTHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UTHR
Wall Street analysts forecast UTHR stock price to rise
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 503.600
Low
423.00
Averages
534.50
High
645.00
Current: 503.600
Low
423.00
Averages
534.50
High
645.00
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
United Therapeutics Reports Strong Q4 Earnings Exceeding Expectations
- Earnings Beat: United Therapeutics reported Q4 earnings of $7.70 per share, surpassing analyst expectations of $7.09, indicating strong profitability despite sales falling short of forecasts.
- Sales Miss: The company recorded quarterly sales of $790.2 million, which was below the consensus estimate of $813.077 million, reflecting potential fluctuations in market demand impacting revenue growth.
- Positive Outlook: CEO Martine Rothblatt, Ph.D., highlighted that the ADVANCE OUTCOMES and TETON-1 clinical programs are on the verge of releasing pivotal data, which could unlock significant new treatment options for patients and signal a period of transformational growth for the company.
- Stock Reaction: Despite the earnings beat, United Therapeutics shares fell 5.6% to $505.28 on Thursday, indicating market concerns over the sales miss and its implications for future performance.
See More
United Therapeutics' New Drug Plans Pressure Partner and Rival Stocks
- New Drug Launch Plans: United Therapeutics (UTHR) announced plans to launch a new drug device formulation of its lung therapy treprostinil next year, which led to a ~38% drop in partner MannKind (MNKD) shares and a ~10% decline in rival Liquidia (LQDA) shares.
- Market Reaction: The significant stock declines of MannKind and Liquidia reflect strong market interest in United's new product, Tresmi, designed to reduce the primary side effect of dry powder inhalers—coughing—by up to 90% based on preliminary human studies.
- Patent Litigation Context: Despite ongoing patent litigation with United, Liquidia plans to launch its dry powder formulation Yutrepia in 2025, intensifying market competition and potentially impacting MannKind's market share.
- FDA Filing Plans: United Therapeutics expects to file for FDA approval for PAH and PH-ILD this year, with CEO Martine Rothblatt stating that the new product will change patient reliance on treatments and reduce discontinuation due to cough.
See More
MannKind Faces Uncertainty Over Tyvaso DPI Royalties
- New Product Impact: United Therapeutics' launch of Tresmi, which could replace Tyvaso DPI, introduces uncertainty for MannKind regarding long-term royalty revenues, as evidenced by a 38% drop in MannKind's stock on Wednesday, reflecting market concerns about future income.
- Market Reaction: Despite the significant selloff, H.C. Wainwright analyst noted that the decline may underestimate the potential value of the DPI formulation in the long term, maintaining a ‘Buy’ rating with an $11 price target on MannKind shares.
- Revenue Growth: MannKind reported a 26% revenue increase in the first nine months of 2025, primarily attributed to rising royalties from Tyvaso DPI, underscoring the product's significance in the market.
- User Sentiment Shift: On Stocktwits, retail sentiment around MannKind and United Therapeutics shifted from ‘bearish’ to ‘bullish’ in the past 24 hours, indicating a more optimistic outlook among investors regarding future developments.
See More
United Therapeutics Q4 2025 Earnings Call Highlights
- New Product Launch: CEO Martine Rothblatt announced the introduction of [Tresmi], a soft mist inhaler designed to reduce coughing by up to 90%, with plans to file for approval this year and launch next year, marking a significant breakthrough in treatment options.
- Financial Performance: Total revenue for Q4 2025 reached $790 million, reflecting a 7% year-over-year growth, while full-year revenue surpassed $3 billion for the first time, demonstrating strong momentum in the pulmonary hypertension treatment market.
- Market Outlook: Rothblatt reiterated the company's commitment to achieving a $4 billion revenue run rate next year, emphasizing that this target does not rely on new product launches, showcasing management's confidence in sustained growth.
- Innovation Progress: The company made significant strides in transplantation and regenerative medicine, successfully completing the first manufactured liver clinical trial and targeting a commercial xenotransplant product by 2030, further solidifying its market leadership.
See More
United Therapeutics Q4 Earnings Beat Expectations
- Earnings Beat: United Therapeutics reported a Q4 GAAP EPS of $7.70, exceeding expectations by $0.94, indicating strong profitability that could bolster investor confidence.
- Revenue Miss: Despite a 7.4% year-over-year revenue increase to $790.2 million, the figure fell short of market expectations by $21.15 million, highlighting challenges in revenue growth amid a competitive biopharmaceutical landscape.
- Positive Market Reaction: The stock market responded favorably to the earnings beat, potentially attracting more investor interest in United Therapeutics' future growth prospects.
- Optimistic Outlook: The company showcased advancements in its organ technology at the J.P. Morgan Healthcare Conference, demonstrating its innovation capabilities in biotechnology, which may lay the groundwork for future revenue growth.
See More
United Therapeutics Reports Record Financial Results for 2025
- Significant Revenue Growth: United Therapeutics achieved total revenues of $3.18 billion in 2025, reflecting an 11% increase year-over-year, marking the fourth consecutive year of record revenue, which underscores the company's strong performance in innovation and market expansion, solidifying its leadership in rare disease treatment.
- Strong Product Sales: Sales of Tyvaso DPI® grew by 25% to $1.29 billion in 2025, primarily driven by an increase in patient numbers and enhanced commercial utilization following the redesign of Medicare Part D benefits, which is expected to propel future revenue growth.
- Net Income Increase: The net income for 2025 reached $1.33 billion, a 12% increase from 2024, with earnings per share at $30.13, reflecting effective strategies in cost control and sales growth, thereby boosting investor confidence.
- Increased R&D Investment: Research and development expenses rose to $550 million in 2025, a 14% increase, primarily allocated to projects involving manufactured organs and drug delivery devices, indicating the company's commitment to long-term innovation and sustainability to meet the growing patient demand.
See More
United Therapeutics Reports Strong Q4 Earnings Exceeding Expectations
- Earnings Beat: United Therapeutics reported Q4 earnings of $7.70 per share, surpassing analyst expectations of $7.09, indicating strong profitability despite sales falling short of forecasts.
- Sales Miss: The company recorded quarterly sales of $790.2 million, which was below the consensus estimate of $813.077 million, reflecting potential fluctuations in market demand impacting revenue growth.
- Positive Outlook: CEO Martine Rothblatt, Ph.D., highlighted that the ADVANCE OUTCOMES and TETON-1 clinical programs are on the verge of releasing pivotal data, which could unlock significant new treatment options for patients and signal a period of transformational growth for the company.
- Stock Reaction: Despite the earnings beat, United Therapeutics shares fell 5.6% to $505.28 on Thursday, indicating market concerns over the sales miss and its implications for future performance.
See More
United Therapeutics' New Drug Plans Pressure Partner and Rival Stocks
- New Drug Launch Plans: United Therapeutics (UTHR) announced plans to launch a new drug device formulation of its lung therapy treprostinil next year, which led to a ~38% drop in partner MannKind (MNKD) shares and a ~10% decline in rival Liquidia (LQDA) shares.
- Market Reaction: The significant stock declines of MannKind and Liquidia reflect strong market interest in United's new product, Tresmi, designed to reduce the primary side effect of dry powder inhalers—coughing—by up to 90% based on preliminary human studies.
- Patent Litigation Context: Despite ongoing patent litigation with United, Liquidia plans to launch its dry powder formulation Yutrepia in 2025, intensifying market competition and potentially impacting MannKind's market share.
- FDA Filing Plans: United Therapeutics expects to file for FDA approval for PAH and PH-ILD this year, with CEO Martine Rothblatt stating that the new product will change patient reliance on treatments and reduce discontinuation due to cough.
See More
MannKind Faces Uncertainty Over Tyvaso DPI Royalties
- New Product Impact: United Therapeutics' launch of Tresmi, which could replace Tyvaso DPI, introduces uncertainty for MannKind regarding long-term royalty revenues, as evidenced by a 38% drop in MannKind's stock on Wednesday, reflecting market concerns about future income.
- Market Reaction: Despite the significant selloff, H.C. Wainwright analyst noted that the decline may underestimate the potential value of the DPI formulation in the long term, maintaining a ‘Buy’ rating with an $11 price target on MannKind shares.
- Revenue Growth: MannKind reported a 26% revenue increase in the first nine months of 2025, primarily attributed to rising royalties from Tyvaso DPI, underscoring the product's significance in the market.
- User Sentiment Shift: On Stocktwits, retail sentiment around MannKind and United Therapeutics shifted from ‘bearish’ to ‘bullish’ in the past 24 hours, indicating a more optimistic outlook among investors regarding future developments.
See More
United Therapeutics Q4 2025 Earnings Call Highlights
- New Product Launch: CEO Martine Rothblatt announced the introduction of [Tresmi], a soft mist inhaler designed to reduce coughing by up to 90%, with plans to file for approval this year and launch next year, marking a significant breakthrough in treatment options.
- Financial Performance: Total revenue for Q4 2025 reached $790 million, reflecting a 7% year-over-year growth, while full-year revenue surpassed $3 billion for the first time, demonstrating strong momentum in the pulmonary hypertension treatment market.
- Market Outlook: Rothblatt reiterated the company's commitment to achieving a $4 billion revenue run rate next year, emphasizing that this target does not rely on new product launches, showcasing management's confidence in sustained growth.
- Innovation Progress: The company made significant strides in transplantation and regenerative medicine, successfully completing the first manufactured liver clinical trial and targeting a commercial xenotransplant product by 2030, further solidifying its market leadership.
See More
United Therapeutics Q4 Earnings Beat Expectations
- Earnings Beat: United Therapeutics reported a Q4 GAAP EPS of $7.70, exceeding expectations by $0.94, indicating strong profitability that could bolster investor confidence.
- Revenue Miss: Despite a 7.4% year-over-year revenue increase to $790.2 million, the figure fell short of market expectations by $21.15 million, highlighting challenges in revenue growth amid a competitive biopharmaceutical landscape.
- Positive Market Reaction: The stock market responded favorably to the earnings beat, potentially attracting more investor interest in United Therapeutics' future growth prospects.
- Optimistic Outlook: The company showcased advancements in its organ technology at the J.P. Morgan Healthcare Conference, demonstrating its innovation capabilities in biotechnology, which may lay the groundwork for future revenue growth.
See More
United Therapeutics Reports Record Financial Results for 2025
- Significant Revenue Growth: United Therapeutics achieved total revenues of $3.18 billion in 2025, reflecting an 11% increase year-over-year, marking the fourth consecutive year of record revenue, which underscores the company's strong performance in innovation and market expansion, solidifying its leadership in rare disease treatment.
- Strong Product Sales: Sales of Tyvaso DPI® grew by 25% to $1.29 billion in 2025, primarily driven by an increase in patient numbers and enhanced commercial utilization following the redesign of Medicare Part D benefits, which is expected to propel future revenue growth.
- Net Income Increase: The net income for 2025 reached $1.33 billion, a 12% increase from 2024, with earnings per share at $30.13, reflecting effective strategies in cost control and sales growth, thereby boosting investor confidence.
- Increased R&D Investment: Research and development expenses rose to $550 million in 2025, a 14% increase, primarily allocated to projects involving manufactured organs and drug delivery devices, indicating the company's commitment to long-term innovation and sustainability to meet the growing patient demand.
See More
